Understanding HIV-1 protease autoprocessing for novel therapeutic development

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Loeb DD, Swanstrom R, Everitt L et al. Complete mutagenesis of the HIV-1 protease. Nature340(6232),397–400 (1989).
  Medline CASGoogle Scholar
• 2  Oroszlan S, Luftig RB. Retroviral proteinases. Curr. Top. Microbiol. Immunol.157,153–185 (1990).
  Medline CASGoogle Scholar
• 3  Partin K, Zybarth G, Ehrlich L et al. Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA88(11),4776–4780 (1991).
  Medline CASGoogle Scholar
• 4  Huang M, Orenstein JM, Martin MA, Freed EO. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol.69,6810–6818 (1995).
  Medline CASGoogle Scholar
• 5  Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B. Aspartic proteases in drug discovery. Curr. Pharm. Des.13(3),271–285 (2007).
  Medline CASGoogle Scholar
• 6  Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science220(4599),868–871 (1983).
  Medline CASGoogle Scholar
• 7  Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In: Retroviruses. Coffin JM, Hughes SH, Varmus HE (Eds). Cold Spring Harbor Laboratory Press, NY, USA (1997).
  Google Scholar
• 8  Parkin NT, Chamorro M, Varmus HE. Human immunodeficiency virus type 1 GagPol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo. J. Virol.66(8),5147–5151 (1992).
  Medline CASGoogle Scholar
• 9  Hung M, Patel P, Davis S, Green SR. Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication. J. Virol.72(6),4819–4824 (1998).
  Medline CASGoogle Scholar
• 10  Chen C, Montelaro RC. Characterization of RNA elements that regulate GagPol ribosomal frameshifting in equine infectious anemia virus. J. Virol.77(19),10280–10287 (2003).
  Medline CASGoogle Scholar
• 11  Louis JM, Weber IT, Tozser J, Clore GM, Gronenborn AM. HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv. Pharmacol.49,111–146 (2000).
  Medline CASGoogle Scholar
• 12  Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun.27(2),157–162 (1967).
  Medline CASGoogle Scholar
• 13  Prejdova J, Soucek M, Konvalinka J. Determining and overcoming resistance to HIV protease inhibitors. Curr. Drug Targets Infect. Disord.4(2),137–152 (2004).
  Medline CASGoogle Scholar
• 14  Pettit SC, Clemente JC, Jeung JA, Dunn BM, Kaplan AH. Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J. Virol.79(16),10601–10607 (2005).
  Medline CASGoogle Scholar
• 15  Pettit SC, Lindquist JN, Kaplan AH, Swanstrom R. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology2,66 (2005).
  MedlineGoogle Scholar
• 16  Paulus C, Ludwig C, Wagner R. Contribution of the Gag Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1. Virology330(1),271 (2004).
  Medline CASGoogle Scholar
• 17  Feher A, Weber IT, Bagossi P et al. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur. J. Biochem.269(16),4114–4120 (2002).
  Medline CASGoogle Scholar
• 18  Zhou J, Chen CH, Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3´,3´-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J. Virol.80(24),12095–12101 (2006).
  Medline CASGoogle Scholar
• 19  Nijhuis M, van Maarseveen NM, Lastere S et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med.4(1),e36 (2007).
  MedlineGoogle Scholar
• 20  Adamson CS, Sakalian M, Salzwedel K, Freed EO. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat. Retrovirology7,36 (2010).
  MedlineGoogle Scholar
• 21  Kohl NE, Emini EA, Schleif WA et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl Acad. Sci. USA85(13),4686–4690 (1988).
  Medline CASGoogle Scholar
• 22  Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B. Overexpression of the HIV-1 Gag Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology193(2),661–671 (1993).
  Medline CASGoogle Scholar
• 23  Krausslich HG. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc. Natl Acad. Sci. USA88(8),3213–3217 (1991).
  Medline CASGoogle Scholar
• 24  Kaplan AH, Zack JA, Knigge M et al. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol.67(7),4050–4055 (1993).
  Medline CASGoogle Scholar
• 25  Wiegers K, Rutter G, Kottler H et al. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol.72(4),2846–2854 (1998).
  Medline CASGoogle Scholar
• 26  Li F, Goila-Gaur R, Salzwedel K et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl Acad. Sci. USA100(23),13555–13560 (2003).
  Medline CASGoogle Scholar
• 27  Dulude D, Berchiche YA, Gendron K, Brakier-Gingras L, Heveker N. Decreasing the frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1. Virology345(1),127–136 (2006).
  Medline CASGoogle Scholar
• 28  Skalka AM. Retroviral proteases: first glimpses at the anatomy of a processing machine. Cell56(6),911–913 (1989).
  Medline CASGoogle Scholar
• 29  Darke PL, Huff JR. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol.25,399–454 (1994).
  Medline CASGoogle Scholar
• 30  Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct.27,249–284 (1998).
  Medline CASGoogle Scholar
• 31  Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta1477,16–34 (2000).
  Medline CASGoogle Scholar
• 32  Dunn BM, Goodenow MM, Gustchina A, Wlodawer A. Retroviral proteases. Genome Biol.3(4),reviews3006–reviews3006.7 (2002).
  MedlineGoogle Scholar
• 33  Vondrasek J, Wlodawer A. HIVdb: a database of the structures of human immunodeficiency virus protease. Proteins49(4),429–431 (2002).
  Medline CASGoogle Scholar
• 34  King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin. Pharmacokinet.45(7),665–682 (2006).
  Medline CASGoogle Scholar
• 35  Wensing AM, Van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res.85(1),59–74 (2010).
  Medline CASGoogle Scholar
• 36  Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov.5(9),785–799 (2006).
  Medline CASGoogle Scholar
• 37  Sielecki AR, Fedorov AA, Boodhoo A, Andreeva NS, James MN. Molecular and crystal structures of monoclinic porcine pepsin refined at 1.8 A resolution. J. Mol. Biol.214(1),143–170 (1990).
  Medline CASGoogle Scholar
• 38  Baldwin ET, Bhat TN, Gulnik S et al. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc. Natl Acad. Sci. USA90(14),6796–6800 (1993).
  Medline CASGoogle Scholar
• 39  Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature329(6137),351–354 (1987).
  Medline CASGoogle Scholar
• 40  Bannwarth L, Reboud-Ravaux M. An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface. Biochem. Soc. Trans.35(Pt 3),551–554 (2007).
  Medline CASGoogle Scholar
• 41  Heaslet H, Rosenfeld R, Giffin M et al. Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr. D Biol. Crystallogr.63(Pt 8),866–875 (2007).
  Medline CASGoogle Scholar
• 42  Ishima R, Ghirlando R, Tozser J et al. Folded monomer of HIV-1 protease. J. Biol. Chem.276(52),49110–49116 (2001).
  Medline CASGoogle Scholar
• 43  Ishima R, Torchia DA, Lynch SM, Gronenborn AM, Louis JM. Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J. Biol. Chem.278(44),43311–43319 (2003).
  Medline CASGoogle Scholar
• 44  Tie Y, Boross PI, Wang YF et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol.338(2),341–352 (2004).
  Medline CASGoogle Scholar
• 45  Tie Y, Boross PI, Wang YF et al. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J.272(20),5265–5277 (2005).
  Medline CASGoogle Scholar
• 46  Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J. Virol.80(7),3607–3616 (2006).
  Medline CASGoogle Scholar
• 47  Sayer JM, Liu F, Ishima R, Weber IT, Louis JM. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J. Biol. Chem.283(19),13459–13470 (2008).
  Medline CASGoogle Scholar
• 48  Ishima R, Gong Q, Tie Y, Weber IT, Louis JM. Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease. Proteins78(4),1015–1025 (2009).
  Google Scholar
• 49  Mittl PR, Grutter MG. Opportunities for structure-based design of protease-directed drugs. Curr. Opin. Struct. Biol.16(6),769–775 (2006).
  Medline CASGoogle Scholar
• 50  Louis JM, Clore GM, Gronenborn AM. Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat. Struct. Biol.6,868–875 (1999).
  Medline CASGoogle Scholar
• 51  Toth MV, Marshall GR. A simple, continuous fluorometric assay for HIV protease. Int. J. Pept. Protein Res.36(6),544–550 (1990).
  Medline CASGoogle Scholar
• 52  Tozser J, Blaha I, Copeland TD, Wondrak EM, Oroszlan S. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and GagPol polyproteins. FEBS Lett.281(1–2),77–80 (1991).
  Medline CASGoogle Scholar
• 53  Pettit SC, Moody MD, Wehbie RS et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol.68(12),8017–8027 (1994).
  Medline CASGoogle Scholar
• 54  Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol.76(20),10226–10233 (2002).
  Medline CASGoogle Scholar
• 55  Lee SK, Potempa M, Kolli M et al. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J. Biol. Chem.287(16),13279–13290 (2012).▪ Demonstrates that HIV-1 protease activity is modulated by complex interactions beyond the catalytic site and the substrate peptide.
  Medline CASGoogle Scholar
• 56  Breuer S, Sepulveda H, Chen Y, Trotter J, Torbett BE. A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry50(20),4371–4381 (2011).
  Medline CASGoogle Scholar
• 57  Louis JM, Aniana A, Weber IT, Sayer JM. Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc. Natl Acad. Sci. USA108(22),9072–9077 (2011).▪ Reveals that precursor proteases are less responsive than the mature proteases to clinical inhibtors.
  MedlineGoogle Scholar
• 58  Shehu-Xhilaga M, Kraeusslich HG, Pettit S et al. Proteolytic processing of the P2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J. Virol.75(19),9156–9164 (2001).
  Medline CASGoogle Scholar
• 59  Pettit SC, Gulnik S, Everitt L, Kaplan AH. The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J. Virol.77(1),366–374 (2003).
  Medline CASGoogle Scholar
• 60  Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J. Virol.78(16),8477–8485 (2004).
  Medline CASGoogle Scholar
• 61  Daniels SI, Davis DA, Soule EE et al. The initial step in human immunodeficiency virus type 1 GagProPol processing can be regulated by reversible oxidation. PLoS ONE5(10),e13595 (2010).
  MedlineGoogle Scholar
• 62  Debouck C, Gorniak JG, Strickler JE et al. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc. Natl Acad. Sci. USA84(24),8903–8906 (1987).
  Medline CASGoogle Scholar
• 63  Huang L, Sayer JM, Swinford M, Louis JM, Chen C. Modulation of human immunodeficiency virus type 1 protease autoprocessing by charge properties of surface residue 69. J. Virol.83(15),7789–7793 (2009).▪ Reports on the role of H69 in regulating precursor processing.
  Medline CASGoogle Scholar
• 64  Huang L, Chen C. Autoprocessing of human immunodeficiency virus type 1 protease miniprecursor fusions in mammalian cells. AIDS Res. Ther.7(1),27 (2010).
  MedlineGoogle Scholar
• 65  Huang L, Hall A, Chen C. Cysteine 95 and other residues influence the regulatory effects of histidine 69 mutations on human immunodeficiency virus type 1 protease autoprocessing. Retrovirology7,24 (2010).▪ Describes a novel cell-based precursor autoprocessing assay that recaptulates many previously observed phenomena.
  MedlineGoogle Scholar
• 66  Huang L, Li Y, Chen C. Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions. Retrovirology8(1),79 (2011).
  Medline CASGoogle Scholar
• 67  Davis DA, Brown CA, Singer KE et al. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. Antiviral Res.72(2),89–99 (2006).
  Medline CASGoogle Scholar
• 68  Louis JM, Ishima R, Torchia DA, Weber IT. HIV-1 protease: structure, dynamics, and inhibition. Adv. Pharmacol.55,261–298 (2007).
  Medline CASGoogle Scholar
• 69  Cherry E, Liang C, Rong L et al. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. J. Mol. Biol.284(1),43–56 (1998).
  Medline CASGoogle Scholar
• 70  Wondrak EM, Nashed NT, Haber MT, Jerina DM, Louis JM. A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation. J. Biol. Chem.271(8),4477–4481 (1996).
  Medline CASGoogle Scholar
• 71  Koh Y, Matsumi S, Das D et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem.282(39),28709–28720 (2007).
  Medline CASGoogle Scholar
• 72  Pan YY, Wang SM, Huang KJ, Chiang CC, Wang CT. Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production. PLoS ONE7(3),e32845 (2012).▪ Reports a fluorescence resonance energy transfer-based method for quantification of precursor dimerization in co-transfected mammalian cells.
  Medline CASGoogle Scholar
• 73  Tessmer U, Krausslich HG. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J. Virol.72(4),3459–3463 (1998).
  Medline CASGoogle Scholar
• 74  Ludwig C, Leiherer A, Wagner R. Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation. J. Virol.82(9),4573–4584 (2008).
  Medline CASGoogle Scholar
• 75  Tang C, Louis JM, Aniana A, Suh JY, Clore GM. Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease. Nature455(7213),693–696 (2008).
  Medline CASGoogle Scholar
• 76  Agniswamy J, Sayer JM, Weber IT, Louis JM. Terminal interface conformations modulate dimer stability prior to amino terminal autoprocessing of HIV-1 protease. Biochemistry51(5),1041–1050 (2012).▪ Structural analysis of complexes formed between a model precursor HIV-protease and darunavir illustrating the terminal interface conformations that destablize precursor dimers.
  Medline CASGoogle Scholar
• 77  Chatterjee A, Mridula P, Mishra RK, Mittal R, Hosur RV. Folding regulates autoprocessing of HIV-1 protease precursor. J. Biol. Chem.280(12),11369–11378 (2005).
  Medline CASGoogle Scholar
• 78  Burnley BT, Afonine PV, Adams PD, Gros P. Modelling dynamics in protein crystal structures by ensemble refinement. eLife1,e00311 (2012).
  MedlineGoogle Scholar
• 79  Sadiq SK, Noe F, De Fabritiis G. Kinetic characterization of the critical step in HIV-1 protease maturation. Proc. Natl Acad. Sci. USA109(50),20449–20454 (2012).
  Medline CASGoogle Scholar
• 80  Rose JR, Salto R, Craik CS. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J. Biol. Chem.268(16),11939–11945 (1993).
  Medline CASGoogle Scholar
• 81  Mildner AM, Rothrock DJ, Leone JW et al. The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry33(32),9405–9413 (1994).
  Medline CASGoogle Scholar
• 82  Louis JM, Nashed NT, Parris KD, Kimmel AR, Jerina DM. Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the GagPol polyprotein. Proc. Natl Acad. Sci. USA91(17),7970–7974 (1994).
  Medline CASGoogle Scholar
• 83  Agniswamy J, Shen CH, Aniana A et al. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry51(13),2819–2828 (2012).
  Medline CASGoogle Scholar
• 84  Erickson-Viitanen S, Manfredi J, Viitanen P et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses5(6),577–591 (1989).
  Medline CASGoogle Scholar
• 85  Krausslich HG, Schneider H, Zybarth G, Carter CA, Wimmer E. Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.J. Virol.62(11),4393–4397 (1988).
  Medline CASGoogle Scholar
• 86  Krausslich HG, Ingraham RH, Skoog MT et al. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc. Natl Acad. Sci. USA86(3),807–811 (1989).
  Medline CASGoogle Scholar
• 87  Koh Y, Aoki M, Danish ML et al. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J. Virol.85(19),10079–10089 (2011).
  Medline CASGoogle Scholar
• 88  Aoki M, Danish ML, Aoki-Ogata H et al. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. J. Virol.86(24),13384–13396 (2012).
  Medline CASGoogle Scholar
• 89  Huang YC, Misquitta S, Blond SY, Adams E, Colman RF. Catalytically active monomer of glutathione S-transferase pi and key residues involved in the electrostatic interaction between subunits. J. Biol. Chem.283(47),32880–32888 (2008).
  Medline CASGoogle Scholar
• 90  Fabrini R, De Luca A, Stella L et al. Monomer–dimer equilibrium in glutathione transferases: a critical re-examination. Biochemistry48(43),10473–10482 (2009).
  Medline CASGoogle Scholar
• 91  Kaplan W, Husler P, Klump H et al. Conformational stability of pGEX-expressed Schistosoma japonicum glutathione S-transferase: a detoxification enzyme and fusion-protein affinity tag. Protein Sci.6(2),399–406 (1997).
  Medline CASGoogle Scholar
• 92  Wan M, Takagi M, Loh BN, Xu XZ, Imanaka T. Autoprocessing: an essential step for the activation of HIV-1 protease. Biochem. J.316(Pt 2),569–573 (1996).
  MedlineGoogle Scholar
• 93  Louis JM, McDonald RA, Nashed NT et al. Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.Eur. J. Biochem.199(2),361–369 (1991).
  Medline CASGoogle Scholar
• 94  Ullman EF, Kirakossian H, Singh S et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl Acad. Sci. USA91(12),5426–5430 (1994).
  Medline CASGoogle Scholar
• 95  Ullman EF, Kirakossian H, Switchenko AC et al. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin. Chem.42(9),1518–1526 (1996).
  Medline CASGoogle Scholar
• 96  Mcgiven JA, Sawyer J, Perrett LL et al. A new homogeneous assay for high throughput serological diagnosis of brucellosis in ruminants. J. Immunol. Methods337(1),7–15 (2008).
  Medline CASGoogle Scholar
• 97  Eglen RM, Reisine T, Roby P et al. The use of AlphaScreen technology in HTS: current status. Curr. Chem. Genomics1,2–10 (2008).
  Medline CASGoogle Scholar
• 98  Ishima R, Torchia DA, Louis JM. Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor. J. Biol. Chem.282(23),17190–17199 (2007).
  Medline CASGoogle Scholar
• 99  Bleiber G, Peters S, Martinez R et al. The central region of human immunodeficiency virus type 1 p6 protein (Gag residues S14-I31) is dispensable for the virus in vitro. J. Gen. Virol.85(Pt 4),921–927 (2004).
  Medline CASGoogle Scholar
• 100  Leiherer A, Ludwig C, Wagner R. Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication. J. Virol.83(14),7210–7220 (2009).
  Medline CASGoogle Scholar
• 101  Lee SK, Potempa M, Swanstrom R. The choreography of HIV-1 proteolytic processing and virion assembly. J. Biol. Chem.287(49),40867–40874 (2012).
  Medline CASGoogle Scholar
• 102  Todd MJ, Semo N, Freire E. The structural stability of the HIV-1 protease. J. Mol. Biol.283(2),475–488 (1998).
  Medline CASGoogle Scholar
• 103  Hamacher K. Relating sequence evolution of HIV1-protease to its underlying molecular mechanics. Gene422(1–2),30–36 (2008).
  Medline CASGoogle Scholar
• 104  Rozzelle JE, Dauber DS, Todd S, Kelley R, Craik CS. Macromolecular inhibitors of HIV-1 protease. Characterization of designed heterodimers. J. Biol. Chem.275(10),7080–7086 (2000).
  Medline CASGoogle Scholar
• 105  Miklossy G, Tozser J, Kadas J et al. Novel macromolecular inhibitors of human immunodeficiency virus-1 protease. Protein Eng. Des. Sel.21(7),453–461 (2008).
  Medline CASGoogle Scholar
• 106  Camarasa MJ, Velazquez S, San-Felix A, Perez-Perez MJ, Gago F. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? Antiviral Res.71(2–3),260–267 (2006).
  Medline CASGoogle Scholar
• 107  Davis DA, Tebbs IR, Daniels SI et al. Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach. Biochem. J.419(2),497–506 (2009).
  Medline CASGoogle Scholar
• 108  Karlstrom AR, Levine RL. Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc. Natl Acad. Sci. USA88(13),5552–5556 (1991).
  Medline CASGoogle Scholar
• 109  Karlstrom AR, Shames BD, Levine RL. Reactivity of cysteine residues in the protease from human immunodeficiency virus: identification of a surface-exposed region which affects enzyme function. Arch. Biochem. Biophys.304(1),163–169 (1993).
  Medline CASGoogle Scholar
• 110  Danielson H, Lindgren MT, Markgren PO, Nillroth U. Investigation of an allosteric site of HIV-1 proteinase involved in inhibition by Cu²⁺. Adv. Exp. Med. Biol.436,99–103 (1998).
  Medline CASGoogle Scholar
• 111  Davis DA, Dorsey K, Wingfield PT et al. Regulation of HIV-1 protease activity through cysteine modification. Biochemistry35(7),2482–2488 (1996).
  Medline CASGoogle Scholar
• 112  Davis DA, Newcomb FM, Starke DW et al. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J. Biol. Chem.272(41),25935–25940 (1997).
  Medline CASGoogle Scholar
• 113  Davis DA, Brown CA, Newcomb FM et al. Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation. J. Virol.77(5),3319–3325 (2003).
  Medline CASGoogle Scholar
• 114  Chang MW, Giffin MJ, Muller R et al. Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem. J.429(3),527–532 (2010).
  Medline CASGoogle Scholar
• 115  Freed EO. Viral late domains. J. Virol.76(10),4679–4687 (2002).
  Medline CASGoogle Scholar
• 116  Freed EO. HIV-1 and the host cell: an intimate association. Trends Microbiol.12(4),170–177 (2004).
  Medline CASGoogle Scholar
• 117  Morita E, Sundquist WI. Retrovirus budding. Annu. Rev. Cell Dev. Biol.20,395–425 (2004).
  Medline CASGoogle Scholar
• 118  Goff SP. Host factors exploited by retroviruses. Nat. Rev. Microbiol.5(4),253–263 (2007).
  Medline CASGoogle Scholar
• 119  Anderson J, Schiffer C, Lee SK, Swanstrom R. Viral protease inhibitors. Handbook Exp. Pharmacol.189(189),85–110 (2009).
  Medline CASGoogle Scholar